Navigation Links
SynCo Bio Partners Completes Manufacture and Release of ActoGeniX' Lead Product for Phase II Clinical Trials
Date:5/14/2008

AMSTERDAM, May 14 /PRNewswire/ -- SynCo Bio Partners B.V., a leading GMP biopharmaceutical manufacturer, announced today that it has completed the manufacture and release of ActoGeniX' drug substance AG011 for use in a Phase II clinical trial with ulcerative colitis patients.

ActoGeniX is focused on the development and commercialization of ActoBiotics(TM), a novel class of protein-based biopharmaceuticals that can be orally administered. The Company's lead product AG011 is an ActoBiotic(TM) for treatment of inflammatory bowel disease and has previously been successfully tested in a Phase I clinical trial with Crohn's disease patients.

To provide the AG011 drug product required for the Phase II studies, due to start this summer, SynCo has developed and scaled up the manufacturing process involving cultivation, purification and lyophilisation of AG011. Although the project involved several parties, working virtually simultaneously on different aspects, the GMP batches were produced within the agreed timelines.

Announcing the successful completion of the project, Pierre Warffemius, CEO, said, "Having ActoGeniX choose us to manufacture the GMP batches for their Phase II clinical trials is a clear endorsement of our growing reputation for manufacturing live biopharmaceuticals. The fact that we were able to work on a multi-agency project and deliver the drug substance on time is also an excellent example of project management capabilities."

Mark Vaeck, CEO of ActoGeniX, "The move from Phase I to Phase II clinical trials is a critical step for ActoGeniX so it was imperative that we worked with a GMP-accredited contract manufacturing organisation that had a proven track record in developing processes for biopharmaceuticals, as well as commercial manufacturing capabilities."

ActoGeniX will, in the coming weeks, file the regulatory applications to obtain approval for the start of its AG011 clinical trial during this summer. ActoGeniX
'/>"/>

SOURCE SynCo Bio Partners B.V.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
2. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
3. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
4. GenVault Partnership with Genome Quebec Brings $3.3 Million Sale of Dynamic Archive Product
5. ADVENTRX Pharmaceuticals to Present at the 2007 Thomas Weisel Partners Healthcare Conference
6. Caliper Life Sciences Presentation at Thomas Weisel Partners Healthcare Conference to be Webcast
7. SuperGen to Present at Thomas Weisel Partners Healthcare Conference September 5th
8. NxStage Medical to Present at the Thomas Weisel Partners Healthcare Conference on September 5, 2007
9. AspenBio Pharma to Present at the Roth Capital Partners New York Investor Conference
10. Tutogen Medical, Inc. to Present at the Roth Capital Partners 2007 New York Conference
11. Thomas Weisel Partners 2007 Healthcare Conference To Webcast Millennium Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 2014 Deep Research Report on ... in-depth research report on the Ammonium Bifluoride market, ... classification, application, and industry chain structure as well ... market analysis, including China’s domestic market as well ... China, Japan etc. regions) industry analysis covering macroeconomic ...
(Date:11/26/2014)... 2014 The Alliance for Safe ... of European physicians at the "1 ST ... Therapies" at the Spanish Ministry of Health, Social ... and the Spanish Bioindustry Association (ASEBIO), included regulators ... Spanish oncology and rheumatology societies, representatives from a ...
(Date:11/26/2014)... Charlotte, NC (PRWEB) November 25, 2014 ... High Intensity Focused Ultrasound (HIFU) devices, recently participated ... “ Small Renal Mass 360° .” Key opinion ... and therapeutic advances related to small renal masses ... learn about different ablative technologies in hands-on labs. ...
(Date:11/26/2014)... Chester, OH (PRWEB) November 25, 2014 ... Holdings, has joined the Graphel Carbon Products team as ... in sales, marketing, and customer service for the graphite ... add Miles to our team,” stated Dave Trinkley, VP ... “His wide range of experience in the graphite ...
Breaking Biology Technology:Ammonium Bifluoride Market International Analysis of Manufacturing, Technology & Trends Now at ReportsnReports.com 2Ammonium Bifluoride Market International Analysis of Manufacturing, Technology & Trends Now at ReportsnReports.com 3ASBM Presents European Physicians Survey at Spanish Ministry of Health 2SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 2SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 3Miles Holder Joins Graphel Corporation as Sales/Marketing Manager 2
... Inc., announced today that it has successfully completed a ... Capital on behalf of the MPM Bio IV NVS ... of a Phase 1/2 human clinical study of its ... disease undergoing surgery for arteriovenous fistula (AVF) creation. Additionally, ...
... and Helena Rojas to Director of Global Business Development Operations ... ... International Ltd., a leading provider of multilingual localization, testing and outsourced ... Arney to Vice President of Global Business Development and Helena Rojas ...
... Oncolytics Biotech Inc. (TSX:ONC, NASDAQ: ONCY ) ("Oncolytics" ... the year ended December 31, 2008. , "In 2008, ... Dr. Brad Thompson, President and CEO of Oncolytics. "The ... interim results reported in our US and UK clinical ...
Cached Biology Technology:Proteon Therapeutics Completes $38M Equity Financing; Initiates Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients and Signs Option Agreement With Major Pharmaceutical Company 2Localization and Translation Leader CSOFT International Ltd. Recognizes Efforts of Two Key Members of its Business Development Team 2Localization and Translation Leader CSOFT International Ltd. Recognizes Efforts of Two Key Members of its Business Development Team 3Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008 2Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008 3Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008 4Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008 5Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008 6Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008 7Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008 8Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008 9
(Date:11/21/2014)... 2014 According to a new ... (Video, RFID, Access Control, Intrusion Detection, Parking Management, Under ... Component Service Geography - Global Forecasts to 2020", published ... to be around $25 Billion in 2014 and is ... a CAGR of 8.69%. Browse 116 market ...
(Date:11/21/2014)... NEW YORK , Nov. 19, 2014  Earlier ... Board at New York College, and one of the ... for biosensor signals that are transmitted from Smartphones to ... there were Smartphones and has one of the earliest ... are discussing its usage in the military, child care, ...
(Date:11/21/2014)... MOUNTAIN VIEW, Calif. , Nov. 20, 2014 /PRNewswire/ ... for higher driver efficiency are piloting the North American ... the number of accidents growing, gesture recognition systems that ... will make a mark in the industry. ... of the Automotive Gesture Recognition Market in ...
Breaking Biology News(10 mins):Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4
... healthy human gene to prevent blindness in mice with ... boys. , Writing in the August issue of Molecular ... they successfully used gene therapy in mice to treat ... mothers, who retain their sight, to their sons. , ...
... private practice, government and industry are coming together ... a rapidly growing area of medicine involving minimally ... first two days of the meeting focus on ... The second half of the meeting provides an ...
... their latest discovery, researchers have significantly advanced the ... constant and potentially destructive changes in gene expression. ... Nature Structural & Molecular Biology, the research is ... disease, and the ability to side-step it may ...
Cached Biology News:Gene therapy works in mice to prevent blindness that strikes boys 2Gene therapy works in mice to prevent blindness that strikes boys 3Minimally Invasive Cancer Treatments Highlighted 2Minimally Invasive Cancer Treatments Highlighted 3Study provides insight into cellular defenses against genetic mutation 2Study provides insight into cellular defenses against genetic mutation 3Study provides insight into cellular defenses against genetic mutation 4
in vitro Translation, Accessory Products...
Request Info...
... Origami host strains are K-12 derivatives that ... (trxB) and glutathione reductase (gor) genes, which ... cytoplasm. Studies have shown that expression in ... in another host even though overall expression ...
Request Info...
Biology Products: